A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069
This study is recruiting at 18 US sites in 11 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Solid Tumor
- Recurrent Solid Tumor
- Advanced Solid Tumor
- Urinary Bladder Neoplasm
- Triple Negative Breast Cancer
- Non-small Cell Lung Cancer
- Esophageal Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Cervical Cancer
- Head and Neck Squamous Cell Carcinoma
- Prostate Cancer
- Renal Pelvis Cancer
- Bladder Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Eli Lilly and Company
- Last updated on ClinicalTrials.gov
- October 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- City of Hope National Medical Center · Duarte, CA
- University of California, San Diego (UCSD) - Moores Cancer Center · La Jolla, CA
- UCLA Department of Medicine-Hematology/Oncology · Los Angeles, CA
Colorado · 1
- Sarah Cannon Research Institute at HealthOne · Denver, CO
Illinois · 1
- University of Chicago Hospital · Chicago, IL
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Michigan · 1
- START Midwest Cancer and Hematology Centers of W Michigan · Grand Rapids, MI
Missouri · 1
- Washington University School of Medicine in St. Louis · St Louis, MO
New York · 4
- Columbia University Irving Medical Center · New York, NY
- Icahn School of Medicine at Mount Sinai · New York, NY
- Memorial Sloan Kettering Cancer Center · New York, NY
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute) · New York, NY
Ohio · 1
- University Hospitals Cleveland Medical Center · Cleveland, OH
Tennessee · 1
- Sarah Cannon Research Institute · Nashville, TN
Texas · 2
- University of Texas MD Anderson Cancer Center · Houston, TX
- South Texas Accelerated Research Therapeutics (START) · San Antonio, TX
Utah · 2
- University of Utah - Huntsman Cancer Institute · Salt Lake City, UT
- START Mountain Region · West Valley City, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.